23 withdrawn. 23 Phase 2, 8 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Withdrawn 23 |
| Phase 1 | 8 | Withdrawn 8 |
| Phase 3 | 2 | Withdrawn 2 |
Follow Ischemia: new trials by email Literature Review of Ischemia trials Research Report on Ischemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Colchicine in Patients With Myocardial Infarction Colchicine, Placebo oral tablet - Myocardium; Injury, Myocardial Infarction | Phase 2 | Withdrawn | Shifa Tameer-e-Millat University | 2025-12-01 | 2023-04-12 | |
| The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial. Autologous hMSCs, Autologous Human C-Kit CSCs II, Placebo - Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction | Phase 1 / Phase 2 | Withdrawn | Joshua M Hare | 2025-03-01 | 2020-10-22 | |
| Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI) OPL-0301 Dose 1, OPL-0301 Dose 2, Placebo - Myocardial Infarction | Phase 2 | Withdrawn | Valo Health, Inc. | 2022-09-01 | 2023-02-21 | |
| A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke TB006, Placebo - Acute Ischemic Stroke | Phase 2 | Withdrawn | TrueBinding, Inc. | 2022-07-26 | 2024-01-12 | |
| Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL Fremanezumab, Placebo - Cadasil, Migraine | Phase 2 | Withdrawn | Mayo Clinic | 2021-12-01 | 2022-02-28 | |
| RIGENERA 2.0 Trial rhu G-CSF, optimal standard of care, Myocardial Contrast Echocardiography - Anterior Myocardial Infarction, Heart Failure | Phase 2 | Withdrawn | Catholic University of the Sacred Heart | 2020-01-01 | 2022-03-29 | |
| Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction Evolocumab - ST-elevation Myocardial Infarction | Phase 2 | Withdrawn | Fondazione IRCCS Policlinico San Matteo di Pavia | 2019-11-18 | 2024-11-21 | |
| A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction Drug: Placebo, Drug: Injectable Thymosin beta 4 - Acute Myocardial Infarction, ST Elevation Myocardial Infarction | Phase 2 | Withdrawn | RegeneRx Biopharmaceuticals, Inc. | 2019-07-01 | 2021-09-22 | |
| SINGaporean Program Performed With an eXPANsion Medical Device (SingXpand) Protheracytes - Heart Attack | Phase 1 / Phase 2 | Withdrawn | CellProthera | 2018-11-27 | 2022-06-10 | |
| Autologous BMMNC Combined With HA Therapy for PAOD RV-P1501 - Peripheral Arterial Occlusive Disease, Critical Limb Ischemia | Phase 1 / Phase 2 | Withdrawn | Academia Sinica, Taiwan | 2017-01-17 | 2022-03-15 | |
| Mesenchymal Stromal Cells for Ischemic Stroke MSC Infusion, Placebo Comparator - Ischemic Stroke | Phase 1 / Phase 2 | Withdrawn | Sean Savitz | 2016-12-01 | 2018-04-18 | |
| REperfusion With Cooling in CerebraL Acute IscheMia II Normothermia, Mild hypothermia, Trevo Pro Retriever (Stryker Corp.) - Ischemic Stroke, Hypothermia | Phase 2 | Withdrawn | WellStar Health System | 2016-02-01 | 2016-02-17 | |
| DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization DLBS1033, Placebo - Acute Non-ST Elevation Myocardial Infarction | Phase 2 / Phase 3 | Withdrawn | Dexa Medica Group | 2015-11-01 | 2016-04-20 | |
| Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy Autologous cord blood, Hypothermia - Hypoxic Ischemic Encephalopathy, Cerebral Infarction | Phase 1 / Phase 2 | Withdrawn | Children's Hospital of Fudan University | 2015-09-08 | 2023-12-29 | |
| Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock Single bolus of Placebo of CicloMulsion® (Neurovive)., Single bolus of cyclosporine A (CicloMulsion®, Neurovive) - Acute Myocardial Infarction | Phase 2 | Withdrawn | Hospices Civils de Lyon | 2015-09-01 | 2016-03-16 | |
| Gene Therapy for the Treatment of Chronic Stable Angina VM202 - Myocardial Ischemia | Phase 1 / Phase 2 | Withdrawn | Helixmith Co., Ltd. | 2015-03-01 | 2025-09-25 | |
| Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN) Tenecteplase, Alteplase - Ischemic Stroke | Phase 2 / Phase 3 | Withdrawn | Reza Behrouz, DO | 2015-01-01 | 2015-09-23 | |
| A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI) Stem cells - ST Segment Elevation Myocardial Infarction (STEMI), Allogeneic Mesenchymal Bone Marrow Cells | Phase 2 | Withdrawn | Stemedica Cell Technologies, Inc. | 2013-02-01 | 2017-04-27 | |
| Stem Cell Study for Patients With Heart Failure Autologous Stem Cells - Myocardial Ischemia, Congestive Heart Failure | Phase 2 | Withdrawn | Losordo, Douglas, M.D. | 30 | 2010-09-01 | 2010-09-14 |
| Medical Versus Surgical Management of Moderate Mitral Regurgitation Following Percutaneous Coronary Intervention surgical mitral valve repair w/ mitral valve annuloplasty - Myocardial Infarction, Mitral Regurgitation | Phase 1 / Phase 2 | Withdrawn | Southern Illinois University | 2010-07-01 | 2014-06-16 |
Showing 20 of 23. Sign in to see all of them.
Myocardial Infarction (8) · ST Elevation Myocardial Infarction (5) · Ischemic Stroke (4) · Cerebral Infarction (3) · Heart Failure (3) · Myocardial Ischemia (3) · Stroke (3) · Acute Coronary Syndrome (2) · Cardiovascular Diseases (2) · Coronary Disease (2) · Angina Pectoris (1) · Anterior Wall Myocardial Infarction (1) · Body Temperature Changes (1) · Brain Diseases (1)
Pathological Conditions, Signs and Symptoms (23) · Pathologic Processes (22) · Cardiovascular Diseases (21) · Vascular Diseases (21) · Necrosis (18) · Infarction (17) · Heart Diseases (16) · Myocardial Ischemia (12) · Myocardial Infarction (6) · Brain Diseases (5) · Central Nervous System Diseases (5) · Cerebrovascular Disorders (5) · Nervous System Diseases (5) · Brain Infarction (3)
Colchicine (1) · DLBS 1033 (1) · Fondaparinux (1) · Heparin (1) · Hypothermia, Induced (1) · Mitral Valve Annuloplasty (1) · Percutaneous Coronary Intervention (1) · Reperfusion (1) · TB006 (1) · Tenecteplase (1) · Tissue Plasminogen Activator (1) · WW Domain-Containing Oxidoreductase (1) · erenumab (1) · evolocumab (1) · fremanezumab (1)
Academia Sinica, Taiwan (1) · Catholic University of the Sacred Heart (1) · CellProthera (1) · Children's Hospital of Fudan University (1) · Dexa Medica Group (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Helixmith Co., Ltd. (1) · Hospices Civils de Lyon (1) · Imperial College London (1) · Joshua M Hare (1) · Losordo, Douglas, M.D. (1) · Mallinckrodt (1) · Mayo Clinic (1) · RegeneRx Biopharmaceuticals, Inc. (1) · Reza Behrouz, DO (1)
United States (8) · France (2) · Italy (2) · Canada (1) · China (1) · Indonesia (1) · Pakistan (1) · Singapore (1) · Taiwan (1) · United Kingdom (1)
Antonio Maria Leone, MD, PhD (1) · Christina Vassileva, M.D. (1) · Douglas W. Losordo, M.D. (1) · Eric Bonnefoy-Cudraz, MD, PhD (1) · Eric WF Alton (1) · Filippo Crea, MD (1) · Frederic Flandrin (1) · Ismi Purnawan, SpJP(K), MD (1) · J.J. Finkelstein, BBA (1) · Jahanzeb Malik, MBBS (2011) (1) · James F Meschia (1) · Jonathan R Clague (1) · Joshua M Hare, MD (1) · Muhammad Munawar, SpJP(K), MD (1)
2018 (1)